Introduction {#s01}
============

Soluble or transmembrane proteins in the ER possessing unfolded or misfolded parts in their luminal regions are retrotranslocated back to the cytoplasm and degraded by the proteasome, a series of events termed ER-associated degradation (ERAD)-L ([@bib30]; [@bib28]; [@bib3]).

ERAD-L deals with both glycoproteins (gpERAD) and non-glycoproteins (non-gpERAD). Misfolded parts of non-glycoproteins are most likely recognized by molecular chaperones represented by BiP. In contrast, glycoprotein degradation relies on the structure of N-glycans present on the surface of ERAD-L substrates. Glc~3~Man~9~GlcNAc~2~ attached to the asparagine residue is trimmed by glucosidase I and II to Man~9~GlcNAc~2~, which is in turn trimmed to Man~8~GlcNAc~2~ and then to Man~7~GlcNAc~2~. Man~7~GlcNAc~2~ exposing α1,6-linked mannose is recognized by the lectin molecule for the delivery of ERAD-L substrates to the HRD1 E3 complex present in the ER membrane ([@bib21]; [@bib10]; [@bib15]).

We have recently conducted comprehensive gene knockout (KO) analyses to precisely identify the roles of the four α1,2-mannosidase candidates for the mannose trimming that occurs during ERAD-L, namely ER mannosidase I (ERmanI), EDEM1, EDEM2, and EDEM3. These experiments were performed in chicken DT40 cells using conventional homologous recombination and in human HCT116 cells using the transcription activator-like effector nuclease method. Our results were surprising ([@bib23]). Initial trimming from Man~9~GlcNAc~2~ to Man~8~GlcNAc~2~ was conducted by EDEM2, which had been thought to have no mannosidase activity ([@bib19]), whereas subsequent trimming from Man~8~GlcNAc~2~ to Man~7~GlcNAc~2~ was performed mostly by EDEM3 and to a slight extent by EDEM1. ERmanI appeared to play only a minor role in gpERAD.

Here, by constructing and analyzing DT40 and HCT116 cells simultaneously deficient in EDEM1/2/3, we show that different ERAD pathways are used depending on the severity of misfolding in the ERAD-L substrates and that non-gpERAD has a much more positive role in protein quality control in the ER than its previously proposed role as a backup for gpERAD under ER stress ([@bib29]), as indicated by the finding that non-gpERAD is able to clear severely misfolded glycoproteins from the ER even in the absence of pharmacological ER stress.

Results and discussion {#s02}
======================

We constructed EDEM1/2/3 triple KO (TKO) in both DT40 (gEDEM-TKO; [Fig. S1](http://www.jcb.org/cgi/content/full/jcb.201504109/DC1){#supp1}) and HCT116 (hEDEM-TKO; [Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.201504109/DC1){#supp2}) cells, in which functional EDEM1, EDEM2, or EDEM3 mRNA was not expressed ([Fig. 1, A and C](#fig1){ref-type="fig"}). gEDEM-TKO and hEDEM-TKO cells grew slightly more slowly than respective wild-type (WT) cells ([Fig. 1, A and C](#fig1){ref-type="fig"}). However, ER stress was not elicited in these cells because the levels of three ER stress marker proteins, BiP, ATF4, and XBP1(S), were not elevated (Fig. S2 B). The N-glycan profiles of total cellular glycoproteins revealed that M9 level was markedly elevated in gEDEM-TKO and hEDEM-TKO cells, similarly to WT DT40 and HCT116 cells treated with kifunensine, an inhibitor of α1,2-mannosidases in the ER ([Fig. 1, B and D](#fig1){ref-type="fig"}), as expected from our previous results ([@bib23]). Accordingly, degradation of endogenous ATF6α, an ERAD-Lm (m for membrane protein) substrate containing three potential N-glycosylation sites ([Fig. 3 A](#fig3){ref-type="fig"}) was blocked almost completely in gEDEM-TKO and hEDEM-TKO cells ([Fig. 1, E and F](#fig1){ref-type="fig"}). The extent of this blockade was comparable with that observed in WT cells treated with MG132, a proteasome inhibitor, or kifunensine ([@bib23]). We also found that hATF6α(C)-TAP, an artificial ERAD-Ls (s for soluble protein) substrate containing the luminal region of human ATF6α flanked by the N-terminal signal sequence and C-terminal tandem affinity purification tag ([Fig. 3 A](#fig3){ref-type="fig"}), was stabilized in gEDEM-TKO cells ([Fig. 1 G](#fig1){ref-type="fig"}). During SDS-PAGE, hATF6α(C)-TAP in gEDEM-TKO cells migrated slightly more slowly than in WT cells because of the defect in mannose trimming, and this difference in migration was lost after endoglycosidase H (EndoH) treatment ([Fig. 1 H](#fig1){ref-type="fig"}). Instability of the native protein ATF6α in WT cells may result from intrinsically disordered parts found in its luminal region ([@bib25]).

![**Effect of EDEM-TKO on N-glycan profiles and ATF6α degradation.** (A) RT-PCR to amplify cDNA corresponding to gEDEM1/2/3 mRNA in DT40 cells of various genotypes and doubling times of WT and gEDEM-TKO cells. (B) Isomer composition of N-glycans prepared from total cellular glycoproteins of WT, WT treated with kifunensine (Kif, 10 µg/ml, 6 h), and gEDEM-TKO cells. This experiment was completed once. (C) RT-PCR to amplify cDNA corresponding to hEDEM1/2/3 mRNA in WT and hEDEM-TKO cells and their doubling times. The asterisk denotes a nonspecific band. (D) Isomer composition of N-glycans prepared from total cellular glycoproteins of WT, WT treated with kifunensine (10 µg/ml, 12 h), and hEDEM-TKO cells. This experiment was completed once. (E) Cycloheximide chase to determine the degradation rate of endogenous gATF6 (only one *ATF6* gene in chicken genome) in WT and gEDEM-TKO cells using anti-gATF6 (*n* = 3). (F) Pulse-chase to determine the degradation rate of endogenous hATF6α in WT and hEDEM-TKO cells using anti-hATF6α (*n* = 3). (G) Cycloheximide chase to determine the degradation rate of transfected hATF6α(C)-TAP in WT and gEDEM-TKO cells using anti--c-myc (*n* = 3). (E--G) Means ± SD are shown. \*, P \< 0.05; \*\*, P \< 0.01. (H) Immunoblotting of cell lysates prepared from WT and gEDEM-TKO cells expressing transfected hATF6α(C)-TAP with or without EndoH treatment using anti--c-myc. hATF6α(C)-TAP\* denotes the nonglycosylated hATF6α(C)-TAP.](JCB_201504109_Fig1){#fig1}

We next examined the effect of EDEM-TKO on degradation of the null Hong Kong (NHK) variant of α1-proteinase inhibitor (α1PI), the most frequently used ERAD-Ls substrate ([@bib27]). Similarly to the case of hATF6α(C)-TAP, NHK in gEDEM-TKO cells migrated slightly more slowly than in WT cells during SDS-PAGE, and this difference in migration was lost after EndoH treatment ([Fig. 2 A](#fig2){ref-type="fig"}). In the case of NHK-QQQ, the nonglycosylated version of NHK and its migration positions during SDS-PAGE ([Fig. 2 A](#fig2){ref-type="fig"}), as well as its degradation rate ([Fig. 2 B](#fig2){ref-type="fig"}), did not differ between WT and gEDEM-TKO cells, as expected. However, in marked contrast to the case of ATF6α ([@bib23]), we were surprised to find that NHK was degraded similarly in WT and gEDEM1/2/3 single KO ([Fig. 2 C](#fig2){ref-type="fig"}) and in WT and hEDEM1/2/3 single KO cells ([Fig. 2 F](#fig2){ref-type="fig"}). Furthermore, degradation of NHK was delayed only at early chase periods in gEDEM-TKO ([Fig. 2 D](#fig2){ref-type="fig"}) and hEDEM-TKO ([Fig. 2 G](#fig2){ref-type="fig"}) cells, and NHK was eventually degraded in gEDEM-TKO and hEDEM-TKO cells similarly to the case in WT cells. This delay in early chase period was also observed in WT DT40 ([Fig. 2 E](#fig2){ref-type="fig"}) and HCT116 ([Fig. 2, G and H](#fig2){ref-type="fig"}) cells treated with kifunensine, whereas NHK degradation was significantly delayed at all chase periods in WT DT40 ([Fig. 2 E](#fig2){ref-type="fig"}) and HCT116 ([Fig. 2 H](#fig2){ref-type="fig"}) cells treated with MG132. Kifunensine treatment of hEDEM-TKO cells did not affect the degradation rate of NHK, as expected ([Fig. 2 G](#fig2){ref-type="fig"}). Thus, the fates of ERAD-L substrates in cells defective in mannose trimming differ depending on the substrate examined.

![**Effect of EDEM-TKO on NHK degradation.** (A) Immunoblotting of cell lysates prepared from WT and gEDEM-TKO cells expressing transfected NHK with or without EndoH treatment and those expressing transfected NHK-QQQ, using anti-α1PI. NHK\* denotes the nonglycosylated NHK. (B) Pulse-chase to determine the degradation rate of transfected NHK-QQQ in WT and gEDEM-TKO cells using anti-α1PI (*n* = 3). (C) Pulse-chase to determine the degradation rate of transfected NHK in WT and gEDEM1/2/3 single KO cells using anti-α1PI (*n* = 3). (D) Pulse-chase to determine the degradation rate of transfected NHK in WT and gEDEM-TKO cells using anti-α1PI (*n* = 3). (E) Pulse-chase to determine the degradation rate of transfected NHK in WT DT40 cells and those treated with kifunensine (10 µg/ml) or MG132 (30 µM) using anti-α1PI (*n* = 3). (F) Pulse-chase to determine the degradation rate of transfected NHK in WT and hEDEM1/2/3 single KO cells using anti-α1PI (*n* = 3). (G) Pulse-chase to determine the degradation rate of transfected NHK in WT and hEDEM-TKO cells in the presence or absence of kifunensine (10 µg/ml) using anti-α1PI (*n* = 3). (H) Pulse-chase to determine the degradation rate of transfected NHK in WT HCT116 cells and those treated with kifunensine (10 µg/ml) or MG132 (20 µM) using anti-α1PI (*n* = 3). (B--H) Means ± SD are shown. (D--H) \*, P \< 0.05; \*\*, P \< 0.01.](JCB_201504109_Fig2){#fig2}

We hypothesized that chicken and human cells are able to extract severely misfolded glycoproteins, such as NHK containing C-terminal large truncation, from gpERAD and target them to non-gpERAD, which degrades substrates such as NHK-QQQ ([Fig. 2 B](#fig2){ref-type="fig"}). To probe this hypothesis, we introduced various deletions into hATF6α(C)-TAP to exacerbate its degree of misfolding. At the same time, we removed the 2×IgG binding domain from hATF6α(C)-TAP to make hATF6α(C)-myct, on the basis that the presence of such a folded domain may obscure the effect of deletion on the folding status of hATF6α(C) ([Fig. 3 A](#fig3){ref-type="fig"}). This hATF6α(C)-myct was markedly stabilized in gEDEM-TKO cells ([Fig. 3 C](#fig3){ref-type="fig"}). We then constructed its three deletion mutants ([Fig. 3 A](#fig3){ref-type="fig"}). All four proteins entered the ER and became glycosylated, as they migrated slightly more slowly in gEDEM-TKO cells than in WT cells during SDS-PAGE, and the difference in migration was lost after EndoH treatment ([Fig. 3 B](#fig3){ref-type="fig"}). Cycloheximide chase experiments revealed that the deletion of aa 280--298 did not significantly affect the stability of hATF6α(C)-myct ([Fig. 3 D](#fig3){ref-type="fig"}). In contrast, the Δ111--119, 182--194 mutant and Δ219--270 mutant became very unstable in gEDEM-TKO cells and behaved very similarly to NHK; their degradation was delayed only at the early chase periods in gEDEM-TKO cells, and they were eventually degraded in both WT and gEDEM-TKO cells ([Fig. 3, E and F](#fig3){ref-type="fig"}). It should be noted that degradation of all four glycoproteins was blocked by MG132 treatment in both WT and gEDEM-TKO cells (Fig. S2 C).

![**Effect of EDEM-TKO on hATF6α(C)-myct degradation.** (A) Schematic structures of hATF6α, hATF6α(C)-TAP, hATF6α(C)-myct, and its three deletion mutants. bZIP and TMD denote basic leucine zipper and transmembrane domains, respectively. N indicates a potential glycosylation site. Both the amino acids 111--119 and 182--194 are expected to form an α-helix. (B) Immunoblotting of cell lysates prepared from WT and gEDEM-TKO cells expressing one of the four hATF6α(C) derivatives by transfection with or without EndoH treatment using anti--c-myc. (C--F) Cycloheximide chase of WT and gEDEM-TKO cells expressing one of the four hATF6α(C) derivatives by transfection using anti--c-myc (*n* = 3). Means ± SD are shown. \*, P \< 0.05; \*\*, P \< 0.01.](JCB_201504109_Fig3){#fig3}

To determine whether the folding status of the four glycoproteins is correlated with their fates in gEDEM-TKO cells, we used several approaches. It was previously shown that a denatured glycoprotein is more susceptible to mannose trimming by ERmanI than a native protein ([@bib1]). In this connection, we noticed that when cells were lysed directly in SDS sample buffer, hATF6α(C)-myct1-302 and the Δ280--298 mutant were detected as a single band, whereas the Δ111--119, 182--194 and Δ219--270 mutants were detected as a doublet, although slower bands were predominant ([Fig. S3 A](http://www.jcb.org/cgi/content/full/jcb.201504109/DC1){#supp3}). When cells were lysed with digitonin and then mixed with 2× SDS sample buffer, faster bands of hATF6α(C)-myct1-302 and the Δ280--298 mutant appeared, and levels of faster bands of the Δ111--119, 182--194 and Δ219--270 mutants increased (Fig. S3 A). We interpret this appearance of faster bands upon lysis with digitonin to represent partial deglycosylation of hATF6α(C) derivatives by peptide:N-glycanase (PNGase), an enzyme responsible for deglycosylation of glycoproteins dislocated from the ER to the cytosol ([@bib20]), for three reasons. First, both bands were sensitive to EndoH treatment (Fig. S3 B); second, the appearance of the faster band of the Δ111--119, 182--194 mutant was significantly inhibited by Z-VAD-fmk (Fig. S3 C), which inhibits PNGase; and third, the faster band of the Δ111--119, 182--194 mutant did not appear in mouse embryonic fibroblast (MEF) cells deficient in PNGase but did appear in MEF cells deficient in the cytosolic endo-β-*N*-acetylglucosaminidase (ENGase; Fig. S3 D; [@bib11]). The time course of the appearance of faster bands in PNGase sensitivity assay in cell lysates indicated that the Δ111--119, 182--194 and Δ219--270 mutants were more misfolded than hATF6α(C)-myct1-302 and the Δ280--298 mutant (Fig. S3 E).

It was also previously reported that a misfolded protein is more susceptible to trypsin digestion than a folded protein ([@bib12]; [@bib31]). The results of trypsin sensitivity assay suggested that the Δ111--119, 182--194 and Δ219--270 mutants were more misfolded than hATF6α(C)-myct1-302 and Δ280--298 mutant (Fig. S3 F).

To substantiate our hypothesis further, we determined whether severely misfolded glycoproteins are degraded by non-gpERAD in human cells also. For this, we focused on mouse CD3-δ-ΔTM, an ERAD-Ls substrate containing three potential N-glycosylation sites ([Fig. 4 A](#fig4){ref-type="fig"}; [@bib2]), which is localized in the ER ([Fig. 4 B](#fig4){ref-type="fig"}), because a part of hATF6α(C)-myct1-302 was secreted into medium in HCT116 cells (not depicted), contrary to its full retention in the ER of DT40 cells. The results of the PNGase sensitivity assay in cell lysates suggested that the two insertion mutants were more misfolded than WT ([Fig. 4 C](#fig4){ref-type="fig"}). We found that degradation of exogenously expressed mCD3-δ-ΔTM was delayed in hEDEM-TKO cells ([Fig. 4 D](#fig4){ref-type="fig"}) to a similar extent to that in WT cells treated with MG132 ([Fig. 4 E](#fig4){ref-type="fig"}) or kifunensine (not depicted). Importantly, insertion of 7 aa (Pro-Ala-Pro-Ala-Pro-Ala-Pro) between 33 and 34 aa (mCD3-δ-ΔTM\<33-7aa-34\>) or 70 and 71 aa (mCD3-δ-ΔTM\<70-7aa-71\>), present in the second or sixth β-sheet, respectively, in the case of human CD3-δ (Fig. S3 G) resulted in similar degradation of the mutant proteins in the two types of cells, except for a delay at the early chase period in hEDEM-TKO cells ([Fig. 4 F](#fig4){ref-type="fig"}), despite their localization in the ER ([Fig. 4 B](#fig4){ref-type="fig"}).

![**Effect of EDEM-TKO on mCD3-δ--ΔTM degradation.** (A) Schematic structures of WT and two insertion mutants of mCD3-δ--ΔTM. (B) Immunofluorescence of HCT116 cells expressing transfected WT or insertion mutant of mCD3-δ--ΔTM using anti-HA. (C) PNGase sensitivity assay of WT and two insertion mutants of mCD3-δ--ΔTM expressed in HCT116 cells by transfection (immunoblotting with anti-HA). The asterisk denotes partially deglycosylated mCD3-δ--ΔTM. (D) Pulse-chase to determine the degradation rate of transfected WT mCD3-δ--ΔTM in WT and hEDEM-TKO cells using anti-HA (*n* = 3). (E) Pulse-chase to determine the degradation rate of transfected WT mCD3-δ--ΔTM in WT cells and those treated with 40 µM MG132 using anti-HA. This experiment was completed once. (F) Pulse-chase to determine the degradation rate of transfected insertion mutants of mCD3-δ--ΔTM in WT and hEDEM-TKO cells using anti-HA (*n* = 3). (D--F) Means ± SD are shown. (D and F) \*, P \< 0.05; \*\*, P \< 0.01.](JCB_201504109_Fig4){#fig4}

We further found that the type I transmembrane human protein EMC1 containing three potential N-glycosylation sites ([Fig. 5 A](#fig5){ref-type="fig"}), a subunit of the ER membrane protein complex consisting of six subunits (EMC1--EMC6; [@bib14]), behaved like ATF6α. Endogenous hEMC1 turned over slowly in WT HCT116 cells, and its turnover was delayed in hEDEM-TKO cells ([Fig. 5 B](#fig5){ref-type="fig"}). Exogenously expressed Flag-tagged hEMC1 was localized in the ER ([Fig. 5 C](#fig5){ref-type="fig"}) and behaved very similarly to endogenous hEMC1 ([Fig. 5 E](#fig5){ref-type="fig"}). Importantly, however, its Δ35--220 mutant, which lacks most of the pyrroloquinoline quinone (PQQ) domain containing the β-propeller repeat ([@bib16]), was localized in the ER ([Fig. 5 C](#fig5){ref-type="fig"}), was more sensitive to trypsin and therefore more misfolded than hEMC1-Flag ([Fig. 5 D](#fig5){ref-type="fig"}), and was degraded similarly in the two types of cells, except for a delay at the early chase period in hEDEM-TKO cells ([Fig. 5 E](#fig5){ref-type="fig"}).

![**Effect of EDEM-TKO on hEMC1 degradation.** (A) Schematic structures of WT and deletion mutant of hEMC1. (B) Pulse-chase to determine the degradation rate of endogenous hEMC1 in WT and hEDEM-TKO cells using anti-hEMC1. This experiment was completed once. (C) Immunofluorescence of HCT116 cells expressing transfected hEMC1-Flag or hEMC1-ΔPQQ-Flag using anti-Flag. (D) Trypsin sensitivity assay of hEMC1-Flag and hEMC1-ΔPQQ-Flag expressed in HCT116 cells by transfection (immunoblotting with anti-Flag). The data shown are from a single representative experiment out of two repeats. (E) Pulse-chase to determine the degradation rate of transfected hEMC1-Flag and hEMC1-ΔPQQ-Flag, as well as endogenous hEMC1 in WT and hEDEM-TKO cells using anti-hEMC1 (*n* = 3). Means ± SD are shown. \*, P \< 0.05; \*\*, P \< 0.01. (F) Model. Newly synthesized polypeptides of non-glycoproteins are subjected to productive folding. Folded non-glycoproteins are secreted, whereas unfolded or misfolded proteins are targeted to non-gpERAD for proteasomal degradation. Newly synthesized polypeptides of glycoproteins are subjected to N-glycosylation and productive folding. Folded glycoproteins are secreted, whereas native but unstable glycoproteins, somewhat unfolded glycoproteins, and severely misfolded glycoproteins are subjected to EDEM-mediated mannose trimming, followed by proteasomal degradation via gpERAD. In addition, severely misfolded glycoproteins are subjected to non-gpERAD via protein X.](JCB_201504109_Fig5){#fig5}

Our results identified a previously unnoticed system operating in the ER. Chicken and human cells can degrade severely misfolded glycoproteins in the absence of EDEM-mediated mannose trimming. This novel quality control cannot be easily discerned by knocking down EDEM1/2/3 singularly, and was accordingly identified for the first time here after our construction of EDEM-TKO cells in combination with our comparison of the fates of ATF6α and NHK. Based on the results reported for recombinant human ERmanI ([@bib1]), we consider that ERmanI cannot trim Man~9~GlcNAc~2~ present in native but unstable or somewhat unfolded glycoproteins, leading to marked stabilization of ATF6α in EDEM2 single KO cells ([@bib23]), but can trim Man~9~GlcNAc~2~ present in severely misfolded glycoproteins, such as NHK, to produce Man~8~GlcNAc~2~ in EDEM2 single KO cells, which is trimmed to Man~7~GlcNAc~2~ by EDEM3/1 for proteasomal degradation ([Fig. 2 F](#fig2){ref-type="fig"}). Indeed, degradation of NHK was markedly blocked by kifunensine, which inhibits both ERmanI and EDEM1/2/3, at the early chase period (1.5 h) in HCT116 cells ([Fig. 2, G and H](#fig2){ref-type="fig"}). This also explains the apparent blockade of NHK degradation by kifunensine observed at the early chase periods (1--2 h) in previous studies ([@bib8]; [@bib6]). Complete blockade at 3-h chase ([@bib18]) was not reproduced in either recent studies ([@bib24]; [@bib4]) or here ([Fig. 2, G and H](#fig2){ref-type="fig"}).

This protein structure--based decision is made only in higher eukaryotes because yeast does not possess an efficient non-gpERAD ([@bib13]; [@bib17]). In marked contrast, degradation of NHK-QQQ is much more efficient than that of NHK in both mammalian ([@bib9]) and DT40 cells (compare [Fig. 2 B](#fig2){ref-type="fig"} with [Fig. 2 D](#fig2){ref-type="fig"}). This explains why the delay in NHK degradation at the early chase periods in EDEM-TKO cells was canceled in the later chase periods ([Fig. 2, D and G](#fig2){ref-type="fig"}).

The next obvious question is what molecules extract severely misfolded glycoproteins from gpERAD and target them to non-gpERAD (protein X in [Fig. 5 F](#fig5){ref-type="fig"}). Identification of the switch will further enhance our understanding of the protein quality control operating in the ER.

Materials and methods {#s03}
=====================

Construction of plasmids {#s04}
------------------------

Recombinant DNA techniques were performed according to standard procedures ([@bib26]). The integrity of all constructed plasmids was confirmed by extensive sequencing analyses. Site-directed mutagenesis was performed using Dpn I. p3\*flag-CMV-14 Expression Vector (Sigma-Aldrich) was used to express a protein tagged with Flag at the C terminus. Platinum transcription activator-like effector nuclease plasmids to knock out hEDEM family genes were constructed previously ([@bib23]).

Reagents {#s05}
--------

Puromycin (0.5 µg/ml), histidinol (1 mg/ml), mycophenolic acid (15 µg/ml), blasticidin S (25 µg/ml), G418 (2 mg/ml for DT40 and 0.6 mg/ml for HCT116), and Zeocin (1 mg/ml) were used for the selection and maintenance of drug-resistant clones. Kifunensine was purchased from Cayman Chemical Company, EndoH from EMD Millipore, cycloheximide from Sigma-Aldrich, MG132 from Peptide Institute, Z-VAD-fmk from Promega, trypsin from Nacalai Tesque, and digitonin from Wako Pure Chemical Industries.

Cell culture, transfection, and N-glycan profiling {#s06}
--------------------------------------------------

DT40 cells were cultured and transfected as described previously ([@bib22]). HCT116 cells (ATCC CCL-247) and MEF cells were cultured in Dulbecco's modified Eagle's medium (glucose 4.5 g/liter) supplemented with 10% fetal bovine serum, 2 mM glutamine, and antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) at 37°C in a humidified 5% CO~2~/95% air atmosphere and transfected using Lipofectamine 2000 (Invitrogen) or X-tremeGENE 9 (Roche) according to the manufacturers' instructions. Doubling times were determined by counting cell numbers every 24 h for a total of 120 h for DT40 cells, and every 48 h for a total of 192 h for HCT116 cells. Each value represents the mean of triplicate determinations. Pyridylamination and structural identification of N-glycans of total cellular glycoproteins were performed as described previously ([@bib7]; [@bib23]).

Immunological techniques {#s07}
------------------------

Immunoblotting analysis was performed according to the standard procedure ([@bib26]) as described previously ([@bib22]). Chemiluminescence obtained using Western Blotting Luminol Reagent (Santa Cruz Biotechnology, Inc.) was detected using an LAS-3000mini Lumino Image analyzer (Fujifilm). Rabbit anti--chicken ATF6 ([@bib7]) and anti--human ATF6α ([@bib5]) antibodies were raised previously. Rabbit polyclonal anti-EMC1 antibody, which reacts with both chicken and human EMC1, was raised against human EMC1 (529--943 aa) fused to glutathione *S*-transferase. Anti--c-myc antibody (9E10) was obtained from Wako Pure Chemical Industries, anti-Flag antibody from Sigma-Aldrich, anti-HA antibody from Recenttec, anti-KDEL antibody from Medical and Biological Laboratories, anti-ATF4 and anti-XBP1 antibodies from Santa Cruz Biotechnology, Inc., and anti-α1PI antibody from Dako.

Pulse-chase experiments using 9.8 MBq/dish EASY TAG EXPRESS Protein labeling mix \[^35^S\] (PerkinElmer) and subsequent immunoprecipitation using anti--human ATF6α, anti-α1PI, anti--human EMC1, anti-Flag, or anti-HA antibody and protein A--coupled Sepharose beads (GE Healthcare) were performed according to procedures described previously ([@bib22]).

For immunofluorescence analysis, HCT116 cells transfected using X-tremeGENE 9 were fixed by incubation on ice for 6.5 min in methanol/acetone (1:1). Anti-Sec61β antibody was obtained from Proteintech. Secondary antibodies labeled with FITC and CF594 were obtained from ICN Biomedicals and Biotium, respectively. Microscope images were obtained at room temperature with 40 magnification using a DM IRE2 and confocal software (both from Leica).

PNGase sensitivity assay {#s08}
------------------------

HCT116 cells at 24 h after transfection or DT40 cells at 16 h after transfection were washed with PBS, collected, and suspended in 200 µl buffer A (50 mM Tris/HCl, pH 8.0, containing 1% NP-40 \[for mammalian cells\] or 1% digitonin \[for chicken cells\], 150 mM NaCl, protease inhibitor cocktail \[Nacalai Tesque\], and 20 µM MG132). Lysates were left on ice for 20 min and clarified by centrifugation at 14,000 rpm for 10 min at 4°C. After incubation for various periods on ice, cleared lysates were mixed with 2× SDS sample buffer containing 100 mM dithiothreitol and 2 µM Z-VAD-fmk, boiled for 5 min, and subjected to SDS-PAGE followed by immunoblotting.

Trypsin sensitivity assay {#s09}
-------------------------

DT40 cells or HCT116 cells transfected were washed with PBS three times, collected, and suspended in 250 µl (for DT40 cells) or 400 µl (for HCT116 cells) buffer B (50 mM Tris/HCl, pH 8.0, containing 1% NP-40, 150 mM NaCl, 2 µM Z-VAD-fmk, and 20 µM MG132). Lysates were left on ice for 20 min and clarified by centrifugation at 14,000 rpm for 10 min at 4°C. Cleared lysates were incubated with various concentrations of trypsin for 15 min at 4°C and then mixed with 2× SDS sample buffer containing 100 mM dithiothreitol and 10× protease inhibitor cocktail (Nacalai Tesque), boiled for 5 min, and subjected to SDS-PAGE followed by immunoblotting. The presence of equal amounts of proteins in cleared lysates before trypsin digestion was confirmed by immunoblotting with anti--β-actin antibody.

Southern blot hybridization {#s10}
---------------------------

Southern blot hybridization was performed according to standard procedures ([@bib26]) as described previously ([@bib22]). Specific probes were prepared as described previously ([@bib23]) and labeled with digoxigenin. Subsequent reaction with anti-digoxigenin antibody (Roche) and treatment with the chemiluminescent detection reagent CDP-star (GE Healthcare) were performed according to the manufacturers' specifications. Chemiluminescence was visualized using an LAS-3000mini Lumino Image analyzer (Fujifilm).

Genomic PCR {#s11}
-----------

Homologous recombination in HCT116 cells was confirmed by genomic PCR using a pair of primers described previously ([@bib23]).

RT-PCR {#s12}
------

Total RNA prepared from WT DT40 cells or various KOs (∼5 × 10^6^ cells) and from WT HCT116 cells or various KOs (∼3 × 10^6^ cells) by the acid guanidinium/phenol/chloroform method using ISOGEN (Nippon Gene) was converted to cDNA using Moloney murine leukemia virus reverse transcription (Invitrogen) and random primers. The full-length open reading frame of gEDEM1, gEDEM2, gEDEM3, hEDEM1, hEDEM2, or hEDEM3 was amplified using PrimeSTAR HS DNA polymerase (Takara Bio Inc.) and a pair of primers described previously ([@bib23]).

Construction of gEDEM-TKO DT40 cells {#s13}
------------------------------------

We previously constructed gEDEM1, gEDEM2, or gEDEM3 single KO DT40 cells ([@bib23]). We then constructed double KO cells deficient in gEDEM1 and gEDEM2, gEDEM2 and gEDEM3, and gEDEM1 and gEDEM3 (Fig. S1 A). Homologous recombination was checked by Southern blotting (Fig. S1 B), and RT-PCR analysis revealed the expected expression of each mRNA (Fig. S1 C). We further constructed TKO cells deficient in gEDEM1, gEDEM2, and gEDEM3 (Fig. S1 A, right). Homologous recombination was checked by Southern blotting (Fig. S1 B), and RT-PCR analysis revealed the expected expression of each mRNA (Fig. S1 C).

Construction of hEDEM-TKO HCT116 cells {#s14}
--------------------------------------

We previously constructed hEDEM1, hEDEM2, or hEDEM3 single KO HCT116 cells ([@bib23]). We disrupted the hEDEM2 gene in hEDEM3 single KO cells and then disrupted the hEDEM1 gene in the resulting hEDEM2/3 double KO cells to create hEDEM-TKO HCT116 cells (Fig. S2 A).

Online supplemental material {#s15}
----------------------------

Fig. S1 shows the generation of DT40 cells deficient in two or three of gEDEM1/2/3. Fig. S2 shows the generation and characterization of hEDEM-TKO cells and the effect of MG132 on the stability of hATF6α(C) derivatives in DT40 cells. Fig. S3 shows analysis of folding status of hATF6α(C) derivatives in DT40 cells. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201504109/DC1>. Additional data are available in the JCB DataViewer at <http://dx.doi.org/10.1083/jcb.201504109.dv>.
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